Limitations still exist in technologies for genetic testing.

In addition, very low genetic variation believed to be benign may have either a cumulative effect or change the way other gene functions. Finally, while there has been great progress, scientists have not all genes contribute to identify the disease of the retina. Tomorrow we can create a new gene, disease genesscover that many of the previously inconclusive test reports explains, says Ayyagari.. A related point of confusion is that a clear result is not necessarily exclude a diagnosis of a particular disease. Limitations still exist in technologies for genetic testing, explains Ayyagari.

To the patient, it is advantageous, a molecular diagnostics file have have observed Ayyagari ‘If emerging treatments for these complex genetic diseases,’she says, ‘the individual genotype may determine whether a new treatment is the one that works for these patients. ‘.0 glaucoma Announces U.S. Phase 2a Results for PF – 03,187,207 and is an update available for development NO – prostaglandins Program.

Liu and Chen at this research was Nils Peterson and Graise Lee of North Carolina State University, Vanessa Hull, a doctoral student in joined CSIS, provided Chuntian Lu, a graduate student in MSU sociology section and Dayong Hong the Renmin University of China.

Other entries from category "prevention":

Tag Cloud